Thyroid hormones in¯uence all major metabolic pathways. Their most obvious and well-known action is an increase in basal energy expenditure obtained acting on protein, carbohydrate and lipid metabolism. With speci®c regard to lipid metabolism, thyroid hormones affect synthesis, mobilization and degradation of lipids, although degradation is in¯uenced more than synthesis. The main and best-known effects on lipid metabolism include: (a) enhanced utilization of lipid substrates; (b) increase in the synthesis and mobilization of triglycerides stored in adipose tissue; (c) increase in the concentration of non-esteri®ed fatty acids (NEFA); and (d) increase of lipoprotein-lipase activity. While severe hypothyroidism is usually associated with an increased serum concentration of total cholesterol and atherogenic lipoproteins, the occurrence of acute myocardial infarction (AMI) in hypothyroid patients is not frequent. However, hypothyroid patients appear to have an increased incidence of residual myocardial ischemia following AMI. Even in subclinical hypothyroidism, which is characterized by raised serum TSH levels with normal serum thyroid hormone concentrations, mild hyperlipidemia is present and may contribute to an increased risk of atherogenesis. Prudent substitution therapy with L-thyroxine is indicated in patients with both overt and subclinical hypothyroidism, with or without angina, to counteract the cardiovascular risk resulting from hyper-dyslipidemia.
Introduction
Thyroid hormones in¯uence nearly all major metabolic pathways. Their most obvious and well-known action is the increase in basal energy expenditure obtained acting on protein, carbohydrate and lipid metabolism. They do not intervene in the minute-tominute regulation of metabolism, but rather they modulate the activities of metabolic pathways on a medium-or long-term basis, either by a direct action or by modifying the activity of other regulatory hormones such as insulin, glucagon and catecholamines. The effect of thyroid hormones on protein metabolism is characterized by a profound stimulatory effect on the synthesis of numerous cytosolic and mitochondrial proteins as well as of secretory proteins such as albumin and hormones. Tracer studies in humans have clearly shown that endogenous glucose production and utilization rates are increased by thyroid hormones. All aspects of lipid metabolism including synthesis, mobilization and degradation are in¯uenced by thyroid hormones, but degradation is affected more than synthesis. Thyrotoxicosis is associated with a depletion in the stores of most lipids and with a decrease of their concentration in plasma. This is true for triglycerides, phospholipids and cholesterol. Opposite changes occur in conditions of thyroid hormone de®ciency. The metabolism of different apolipoproteins is also affected. 1 The main and best-known effects of thyroid hormones on lipid metabolism are discussed in the present review.
Effects of thyroid hormones on lipid metabolism

Lipolysis
Thyroid hormones stimulate the utilization of lipid substrates owing to an increased mobilization of triglycerids stored in adipose tissue. Increased concentrations and appearance rates of plasma non-esteri®ed fatty acids (NEFA) and glycerol re¯ect this action. The mechanisms of thyroid hormone action on lipolysis remain unclear. No direct lipolytic effect has been found in vitro. The increased lipolytic rate produced by thyroid hormones in vivo might be related to the increased subcutaneous blood-¯ow or to a modi®cation of the lipolytic action of catecholamines.
Hepatic fatty acid metabolism
There is a great deal of evidence that, in addition to stimulating fatty acids oxidation through an increased NEFA availability, thyroid hormones induce lipogenesis in the liver. The simultaneous stimulation of fatty acid oxidation and synthesis may represent a futile cycle of metabolites contributing to the increased energy expenditure. Hepatic synthesis and output of triglycerides are decreased by thyroid hormones. The synthesis and secretion of very-low density lipoproteins (VLDL) are stimulated.
Fatty acids utilization by extra-hepatic tissues NEFA oxidation is increased by thyroid hormones, as well as plasma triglycerides clearance. Lipoprotein ± lipase activity is elevated in hypothyroid subjects.
Lipoprotein metabolism
Hypothyroidism is a well-known cause of hyperlipidemia in both humans and animals. In hypothyroid patients the most frequent lipid abnormality is hypercholesterolemia, mainly due to an increased concentration of low density lipoproteins (LDL). Elevation of very low density lipoproteins (VLDL) and high density lipoproteins (HDL cholesterol) have also been reported. Plasma triglycerides are increased because of an enhanced esteri®cation of fatty acids at hepatic level. Plasma concentrations of lipoprotein (a) increase in hypothyroidism. Lp(a) has been shown to have a thrombogenic and an atherogenic effect. Epidemiological studies indicate that a greater cardiovascular risk is related to increased plasma concentrations of Lp(a). This lipoprotein favors the deposition of cholesterol in endothelial lesions, thus resulting in an increased atherogenic risk.
While thyrotoxicosis has a profound in¯uence on lipid metabolism, these changes do not produce longterm sequelae. More relevant from the clinical point of view are lipid changes associated with hypothyroidism. As previously discussed, hyperlipidemia occurs in patients with overt hypothyroidism and might be responsible for an increased risk of coronary artery disease (CAD). Plasma levels of total cholesterol and LDL cholesterol are increased in patients with hypothyroidism. However, it is not usually appreciated that hypothyroid patients also have increased plasma levels of HDL cholesterol. In some studies, both the totalaHDL cholesterol ratio and the HDLaLDL cholesterol ratio have been reported to predict the progression of CAD. In other studies only the totalaHDL cholesterol ratio was found to be predictive of CAD. Since both total cholesterol and HDL cholesterol levels are increased in patients with hypothyroidism, there is no obvious reason for increased cardiovascular risk. It is interesting to underline that, as compared with primary hypothyroidism, the lipid pro®le is more atherogenic in secondary hypothyroidism, because the plasma levels of HDL cholesterol are lower in the latter condition. Furthermore, secondary hypothyroidism may coexist with adrenal cortical insuf®ciency, and the latter condition may produce additional negative effects on the cardiovascular system. 2 
Coronary artery disease (CAD) and overt hypothyroidism
Overt hypothyroidism is associated with a number of well-known abnormalities of lipid metabolism and sometimes with hypertension, which may predispose patients to develop andaor may accelerate CAD. The precise mechanism responsible for hypertension in hypothyroidism has not been fully elucidated. Changes in circulating catecholamines, their receptors and the renin ± angiotensin ± aldosterone system have all been implicated. 3 Despite a high prevalence of severe atherosclerosis found at autopsy, hypothyroid patients have a relatively low frequency of angina pectoris and myocardial infarction during life. The question of whether or not hypothyroidism predisposes to the development of ischemic heart disease is a controversial one. 4, 5 Both conditions are relatively common among 40 ± 60 y-old adults in industrialized nations. Epidemiological studies estimate at 0.5 ± 10% the prevalence of hypothyroidism in the general adult ± elderly population screened on the basis of elevated serum TSH. Thus, the coexistence of hypothyroidism and ischemic heart disease might be due only to a statistical coincidence, 6 and a real cause ± effect relationship between the two conditions might not exist. If this assumption is true, why is it that the atherosclerotic lesions observed at autopsy in hypothyroid patients do not result in clinical CAD? This discrepancy is most likely explained by the decreased oxygen demand placed on myocardium in hypothyroid patients.
A more direct association between hypothyroidism and CAD has been postulated in other studies. 7 Interestingly, angina pectoris and myocardial infarction display a rather atypical course in hypothyroid patients. This might be explained by the hypometabolic state associated with hypothyroidism which is probably bene®cial to the ischemic myocardium by lowering energy demands and requirements. Indeed, hypothyroidism is not associated with an unfavorable course of acute myocardial infarction. On the other hand, hypothyroid patients appear to have an increased incidence of residual ischemia after an acute myocardial infarction, which may be explained by the occurrence of a more severe and diffuse CAD in hypothyroidism. 8 
Angina and overt hypothyroidism
Despite a large body of data from clinical, epidemiological and autopsy studies linking overt hypothyroidism to the development of atherosclerotic heart disease, the precise relationship between the two conditions and the pathogenetic mechanisms involved are complex and still poorly understood. Lipid abnormalities associated with myxedema undoubtedly play an important role, but other factors are involved as well. Hypothyroidism, mostly when reaching the severity of myxedema, can profoundly affect the circulation system, resulting in the clinical picture of myxedema heart'. The term myxedema, often used as synonym of severe hypothyroidism, refers to the brawny, nonpitting soft-tissue swelling caused by the accumulation of a proteinaceous extracellular¯uid Thyroid and lipid metabolism E Pucci et al due to thyroid hormone de®ciency. Although peripheral water retention is common in myxedema, the actual blood volume is low. Body weight is modestly increased even in severe myxedema. An important feature of the`myxedema heart' is the pericardial effusion that occurs in up to one-third of patients with long-standing severe hypothyroidism. The above described cardiac abnormalities are mostly`silent' 8 in hypothyroid patients, since they do not produce clinical symptoms for a more prolonged period than in euthyroid individuals. This subclinical course may be related to the tendency of hypothyroid patients to pursue a quiet and inactive life, even appearing sluggish. As a consequence, the heart is insuf®ciently stressed to cause noticeable angina pectoris. In later stages, progression of coronary atherosclerosis, together with other complicating factors such as the anemia of hypothyroidism, cause angina pectoris in 5 ± 10% of hypothyroid patients. 9 Coronary artery disease and subclinical hypothyroidism
The combination of raised serum TSH levels and normal serum concentrations of thyroid hormones in apparently asymptomatic patients is known as`subclinical hypothyroidism'. This disorder is the mildest form of a spectrum of thyroid failures and commonly occurs in the natural history of autoimmune thyroiditis. Thyroid antibodies are often the sole ®nding of autoimmune thyroiditis associated with subclinical hypothyroidism. Whether tissues other than the anterior pituitary recognize that thyroid hormones levels are suboptimal, although highly possible, remains dif®cult to prove.
This state of latent thyroid failure, which should be more properly de®ned as mild hypothyroidism, may persist for years or may evolve to myxedema. In the Whickham survey the annual risk of developing overt hypothyroidism was 4% in women with both raised serum TSH and positive thyroid antibody, 3% if only TSH was raised, and 2% if only thyroid antibodies were positive. 10 Progression rates ranging from 7% to 18% per year were reported in other studies. 10 It is worth emphasizing that the hormonal thyroid secretion should be normal or mildly reduced, but still in the normal range. As a consequence, most metabolic pathways and organ systems in¯uenced by thyroid hormones should be unaffected. In spite of these assumptions, mild complaints consistent with thyroid hormone de®ciency, subtle alterations in myocardial contractility (mainly during exercise), cognitive dysfunction and depression have been reported in patients with subclinical hypothyroidism. 9, 10 Restoration of normal cardiac contractility, improved psychometric tests and reduced hypothyroid symptom rating were observed in some patients after L-thyroxine administration. 10 Mild abnormalities of lipid metabolism have also been reported in subclinical hypothyroidism. 10 Fowler and Swale in 1970 11 described a family in which hypercholesterolemia preceded by many years any evidence of hypothyroidism. This stage of autoimmune thyroiditis characterized by hypercholesterolemia alone was called`premyxedema'. Following this ®rst report, Bastenie et al 12 found a signi®cant association between thyroid antibodies and the occurrence of obesity, hypertension, diabetes mellitus and CAD. In this study a signi®-cantly higher proportion of patients with CAD not associated with obesity, hypertension and diabetes had thyroid antibodies as compared with a normal population. At variance with these early investigations indicating a slight increase of CAD in subjects with positive thyroid antibodies, with or without subclinical hypothyroidism, the Whickham study reported no association between autoimmune thyroiditis, as de®ned by hypothyroidism, raised serum TSH, or positive thyroid antibodies, and CAD. 13 Studies from Tanis et al, 14 Pare et al, 15 Miura et al 16 and Dickman et al, 17 even if con®rming mild alterations of lipid metabolism in patients with subclinical hypothyroidism, failed to demonstrate a clear-cut association between subclinical hypothyroidism and increased incidence of CAD.
Thyroid hormone therapy in hypothyroid patients with cardiac disease
Patients presenting both untreated hypothyroidism and angina pose challenging management problems for the clinician. The physician treating hypothyroid patients with angina will note unusual, exaggerated responses to most medications, such as nitrates, digitalis, diuretics and beta-adrenergic blocking agents. 9 As a consequence, it is necessary to start medical treatment with particularly low-dosage regimens. The endocrinologist, while bringing the patients toward the euthyroid state by increasing doses of thyroid replacement, must consider that angina can appear or worsen. A myocardial infarction may possibly ensue. However, in most cases angina is ameliorated and sometimes disappears during L-thyroxine treatment. 18 This paradox has been accredited to a reversible endocrine cardiomyopathy indistinguishable, in the beginning, from the idiopathic form. However, there is little recent clinical research addressing this issue. Among 55 hypothyroid patients with CAD, administration of thyroid hormones exacerbated heart disease in only nine, while the remainder were unchanged or improved. 19 Generally, for patients having extensive coronary artery disease the potential for exacerbation of angina by replacement of thyroid hormone is greater. In elderly hypothyroid patients Thyroid and lipid metabolism E Pucci et al with coexistent or suspected cardiac disease, L-thyroxine therapy should be initiated with 12.5 ± 25 mgaday, followed by careful increments of 12.5 ± 25 mgaday every 4 ± 8 weeks, to reach the full replacement dose in several months. As previously discussed, L-thyroxine substitution may precipitate angina or myocardial infarction in the elderly with CAD. On the other hand, L-thyroxine substitution ameliorates reversible coronary dysfunction inherent with hypothyroidism and produces bene®cial effects on hypothyroid hyperlypidemia. In hypothyroid patients with CAD, euthyroidism can be achieved with Lthyroxine, although some compromise may be needed in the management of the two conditions. Coronary by-pass or angioplasty can be safely performed before starting L-thyroxine administration. Propranolol may not be effective in reducing the cardiac effects of L-thyroxine replacement therapy in CAD patients. Dihydropyridine calcium channels blockers may be more suitable to control angina in hypothyroid patients given L-thyroxine. Some experts advise cardiac catheterization for any hypothyroid patient with pre-existing angina before initiation of thyroid replacement.
The effect of subclinical hypothyroidism and its treatment upon circulating lipids is also controversial. A meta-analysis of the literature 14 showed that subclinical hypothyroidism is two to three times more frequent in people with elevated plasma total cholesterol, and that plasma total cholesterol is slightly elevated in patients with subclinical hypothyroidism. Restoration of normal TSH levels with L-thyroxine decreased total cholesterol by 0.4 mmolal, producing an average 6% reduction in total cholesterol levels that in hypercholesterolemic patients might contribute to reducing ischemic heart disease. 14 In a recent study, coronary artery disease progression could be prevented by adequate L-thyroxine replacement in hypothyroidism. 19 Thus, thyroid hormones can be protective against atherosclerosis, presumably due to their metabolic effects on lipid metabolism and eventually on plaque progression.
Conclusions
The understanding of the impact of thyroid hormones on lipid metabolism has been considerably improved. Nevertheless, some questions remain to be elucidated. Thyroid hormone de®ciency represents a well-known cause of hyperlipidemia both in overt and subclinical hypothyroid patients. The reported frequencies of dyslipidemia vary considerably due to differences in patients' selection, sex and age distribution, and degree of hypothyroidism. Nevertheless, current evidence suggests that in overt hypothyroidism L-thyroxine therapy is indicated even in patients with a high risk of angina pectoris. Subclinical hypothyroidism could also affect cardiac function and increase the risk of atherosclerotic cardiovascular disease, mainly when associated with other underlying cardiac or metabolic disorders. Even in these cases thyroid hormones, through their metabolic effects, can be useful to protect the cardiovascular system against atherosclerosis.
